Cargando…

Publisher Correction: Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride

Detalles Bibliográficos
Autores principales:	Takizawa, Hotake, Hara, Yuko, Mizobe, Yoshitaka, Ohno, Taisuke, Suzuki, Sadafumi, Inoue, Ken, Takeshita, Eri, Shimizu-Motohashi, Yuko, Ishiyama, Akihiko, Hoshino, Mikio, Komaki, Hirofumi, Takeda, Shin’ichi, Aoki, Yoshitsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Publisher Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005800/ https://www.ncbi.nlm.nih.gov/pubmed/32034287 http://dx.doi.org/10.1038/s41598-020-59351-2

Ejemplares similares

Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2019)

A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy
por: Takeshita, Eri, et al.
Publicado: (2018)

Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial
por: Ishizuka, Takami, et al.
Publicado: (2023)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2018)

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
por: Miyatake, Shouta, et al.
Publicado: (2016)

Childhood‐onset cerebellar ataxia in Japan: A questionnaire‐based survey
por: Ono, Hiroya, et al.
Publicado: (2019)

Severe cardiac involvement with preserved truncated dystrophin expression in Becker muscular dystrophy by +1G>A DMD splice-site mutation: a case report
por: Komaki, Ryouhei, et al.
Publicado: (2020)

Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2014)

Application of Urine-Derived Stem Cells to Cellular Modeling in Neuromuscular and Neurodegenerative Diseases
por: Sato, Mitsuto, et al.
Publicado: (2019)

Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche
por: Gaudichon, Jérémie, et al.
Publicado: (2014)

Epigenetically Reprogramming of Human Embryonic Stem Cells by 3-Deazaneplanocin A and Sodium Butyrate
por: Azghadi, Soheila, et al.
Publicado: (2011)

3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation
por: Fujiwara, Tohru, et al.
Publicado: (2014)

Novel EGFP reporter cell and mouse models for sensitive imaging and quantification of exon skipping
por: Hara, Yuko, et al.
Publicado: (2020)

Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study
por: Komaki, Hirofumi, et al.
Publicado: (2020)

Alteration of the anatomical covariance network after corpus callosotomy in pediatric intractable epilepsy
por: Ueda, Riyo, et al.
Publicado: (2019)

Solid-Phase Synthesis of Difficult Purine-Rich PNAs through Selective Hmb Incorporation: Application to the Total Synthesis of Cell Penetrating Peptide-PNAs
por: Tailhades, Julien, et al.
Publicado: (2017)

Anti-inflammatory and chondroprotective effects of the S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A, in human articular chondrocytes
por: Aury-Landas, Juliette, et al.
Publicado: (2017)

Potential Therapies Using Myogenic Stem Cells Combined with Bio-Engineering Approaches for Treatment of Muscular Dystrophies
por: Motohashi, Norio, et al.
Publicado: (2019)

Tumor Necrosis Factor-Alpha and Apoptosis Induction in Melanoma Cells through Histone Modification by 3-Deazaneplanocin A
por: Tanaka, Ryo, et al.
Publicado: (2013)

Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice
por: Lhuissier, Eva, et al.
Publicado: (2018)

A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A
por: Zeybel, Müjdat, et al.
Publicado: (2017)

Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle
por: Miyatake, Shouta, et al.
Publicado: (2019)

Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)
por: Jiang, Xia, et al.
Publicado: (2015)

3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells
por: Girard, Nicolas, et al.
Publicado: (2014)

Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C
por: Momparler, Richard L., et al.
Publicado: (2021)

Semaphorin 3A promotes activation of Pax7, Myf5, and MyoD through inhibition of emerin expression in activated satellite cells
por: Qahar, Mulan, et al.
Publicado: (2016)

Long-term Observation in Patients with Duchenne Muscular Dystrophy with Early Introduction of a Standing Program Using Knee–ankle–foot Orthoses
por: Fujimoto, Akiko, et al.
Publicado: (2023)

Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status
por: Miyagoe-Suzuki, Yuko, et al.
Publicado: (2017)

Cis-regulatory determinants of MyoD function
por: Soleimani, Vahab D, et al.
Publicado: (2018)

Master control: transcriptional regulation of mammalian Myod
por: Wardle, Fiona C.
Publicado: (2019)

MyoD- and nerve-dependent maintenance of MyoD expression in mature muscle fibres acts through the DRR/PRR element
por: Chargé, Sophie B, et al.
Publicado: (2008)

The Presence of Two MyoD Genes in a Subset of Acanthopterygii Fish Is Associated with a Polyserine Insert in MyoD1
por: White, Lewis J., et al.
Publicado: (2023)

Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide
por: Watanabe, Naoki, et al.
Publicado: (2023)

Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy
por: Verma, Mayank, et al.
Publicado: (2019)

H–d-Phe–d-Pro–Gly methyl ester hydrochloride monohydrate
por: Doi, Mitsunobu, et al.
Publicado: (2008)

3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
por: Ni, Jun, et al.
Publicado: (2019)

Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas
por: Lhuissier, Eva, et al.
Publicado: (2021)

Trends in steroid therapy for Duchenne muscular dystrophy in Japan
por: Takeuchi, Fumi, et al.
Publicado: (2016)

Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma
por: Weintraub, Michael, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_9vkj3uqg4dqf2pk3nes5dg9gph